The role of nutraceuticals of natural origin in the treatment of depressive disorders
DOI:
https://doi.org/10.12775/JEHS.2025.82.60309Keywords
Antidepressants, Depression, Natural products, Polyphenolic antioxidants, Polyunsaturated fatty acids, Probiotics, Vitamins and mineralsAbstract
Introduction: Major Depressive Disorder is a prevalent mental disorder, significantly contributing to the number of disability-adjusted life years and years of healthy life lost to disability. The efficacy of currently available treatment modalities is limited by adverse effects and suboptimal treatment response, highlighting the need for additional therapeutic options. A growing body of evidence suggests that numerous nutraceuticals of natural origin may be implemented in the treatment of depression.
Aim of the study: The aim of the study was to compile and analyze current literature regarding the supplementation with polyunsaturated fatty acids, probiotics, polyphenolic antioxidants, vitamins and minerals in treatment and prevention of depression, both as an adjunct to antidepressants and as a standalone therapy.
Methods and materials: A literature search was conducted using the PubMed database and Google Scholar, focusing on recent publications, primarily from the past 10 years. Additionally, references from selected articles were included in the analysis.
Summary: Recent scientific literature suggests that all analyzed nutraceuticals may be effectively used in the treatment of depression. However, further research, particularly large-scale randomized controlled studies, is crucial to confirm the efficacy of these compounds as treatment modalities.
References
1. Depression in Adults: Treatment and Management. National Institute for Health and Care Excellence (NICE); 2022.
2. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137-150. doi:10.1016/S2215-0366(21)00395-3
3. König H, König HH, Konnopka A. The excess costs of depression: a systematic review and meta-analysis. Epidemiol Psychiatr Sci. 2020;29:e30. doi:10.1017/S2045796019000180
4. Kouba BR, De Araujo Borba L, Borges De Souza P, Gil-Mohapel J, Rodrigues ALS. Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets. Cells. 2024;13(5):423. doi:10.3390/cells13050423
5. Malhi GS, Mann JJ. Depression. The Lancet. 2018;392(10161):2299-2312. doi:10.1016/S0140-6736(18)31948-2
6. Pastis I, Santos MG, Paruchuri A. Exploring the role of inflammation in major depressive disorder: beyond the monoamine hypothesis. Front Behav Neurosci. 2024;17:1282242. doi:10.3389/fnbeh.2023.1282242
7. Jesulola E, Micalos P, Baguley IJ. Understanding the pathophysiology of depression: From monoamines to the neurogenesis hypothesis model - are we there yet? Behav Brain Res. 2018;341:79-90. doi:10.1016/j.bbr.2017.12.025
8. Bauer M, Severus E, Möller HJ, Young AH, WFSBP Task Force on Unipolar Depressive Disorders. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. Int J Psychiatry Clin Pract. 2017;21(3):166-176. doi:10.1080/13651501.2017.1306082
9. Ramaker MJ, Dulawa SC. Identifying fast-onset antidepressants using rodent models. Mol Psychiatry. 2017;22(5):656-665. doi:10.1038/mp.2017.36
10. Bet PM, Hugtenburg JG, Penninx BWJH, Hoogendijk WJG. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013;23(11):1443-1451. doi:10.1016/j.euroneuro.2013.05.001
11. Tvrzicka E, Kremmyda LS, Stankova B, Zak A. FATTY ACIDS AS BIOCOMPOUNDS: THEIR ROLE IN HUMAN METABOLISM, HEALTH AND DISEASE - A REVIEW. PART 1: CLASSIFICATION, DIETARY SOURCES AND BIOLOGICAL FUNCTIONS. Biomed Pap. 2011;155(2):117-130. doi:10.5507/bp.2011.038
12. Zhou L, Xiong JY, Chai YQ, et al. Possible antidepressant mechanisms of omega-3 polyunsaturated fatty acids acting on the central nervous system. Front Psychiatry. 2022;13:933704. doi:10.3389/fpsyt.2022.933704
13. Layé S, Nadjar A, Joffre C, Bazinet RP. Anti-Inflammatory Effects of Omega-3 Fatty Acids in the Brain: Physiological Mechanisms and Relevance to Pharmacology. Dantzer R, ed. Pharmacol Rev. 2018;70(1):12-38. doi:10.1124/pr.117.014092
14. Crupi R, Marino A, Cuzzocrea S. n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity. Curr Med Chem. 2013;20(24):2953-2963. doi:10.2174/09298673113209990140
15. Thesing CS, Bot M, Milaneschi Y, Giltay EJ, Penninx BWJH. Omega-3 polyunsaturated fatty acid levels and dysregulations in biological stress systems. Psychoneuroendocrinology. 2018;97:206-215. doi:10.1016/j.psyneuen.2018.07.002
16. Matsuoka YJ, Sawada N, Mimura M, et al. Dietary fish, n-3 polyunsaturated fatty acid consumption, and depression risk in Japan: a population-based prospective cohort study. Transl Psychiatry. 2017;7(9):e1242-e1242. doi:10.1038/tp.2017.206
17. Husted KS, Bouzinova EV. The importance of n-6/n-3 fatty acids ratio in the major depressive disorder. Medicina (Mex). 2016;52(3):139-147. doi:10.1016/j.medici.2016.05.003
18. Sánchez-Villegas A, Álvarez-Pérez J, Toledo E, et al. Seafood Consumption, Omega-3 Fatty Acids Intake, and Life-Time Prevalence of Depression in the PREDIMED-Plus Trial. Nutrients. 2018;10(12):2000. doi:10.3390/nu10122000
19. Mehdi S, Manohar K, Shariff A, et al. Omega-3 Fatty Acids Supplementation in the Treatment of Depression: An Observational Study. J Pers Med. 2023;13(2):224. doi:10.3390/jpm13020224
20. Gertsik L, Poland RE, Bresee C, Rapaport MH. Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder. J Clin Psychopharmacol. 2012;32(1):61-64. doi:10.1097/JCP.0b013e31823f3b5f
21. Yang B, Lin L, Bazinet RP, et al. Clinical Efficacy and Biological Regulations of ω–3 PUFA-Derived Endocannabinoids in Major Depressive Disorder. Psychother Psychosom. 2019;88(4):215-224. doi:10.1159/000501158
22. Lamon-Fava S, Liu M, Dunlop BW, et al. Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators. Neuropsychopharmacology. 2023;48(6):929-935. doi:10.1038/s41386-022-01527-7
23. Chang JPC, Chang SS, Chen HT, et al. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), somatic and fatigue symptoms in cardiovascular diseases comorbid major depressive disorder (MDD): A randomized controlled trial. Brain Behav Immun. 2023;112:125-131. doi:10.1016/j.bbi.2023.06.008
24. Tayama J, Ogawa S, Nakaya N, et al. Omega-3 polyunsaturated fatty acids and psychological intervention for workers with mild to moderate depression: A double-blind randomized controlled trial. J Affect Disord. 2019;245:364-370. doi:10.1016/j.jad.2018.11.039
25. Okereke OI, Vyas CM, Mischoulon D, et al. Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA. 2021;326(23):2385. doi:10.1001/jama.2021.21187
26. Dziedzic A, Maciak K, Bliźniewska-Kowalska K, Gałecka M, Kobierecka W, Saluk J. The Power of Psychobiotics in Depression: A Modern Approach through the Microbiota–Gut–Brain Axis: A Literature Review. Nutrients. 2024;16(7):1054. doi:10.3390/nu16071054
27. Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 2014;16(7):1024-1033. doi:10.1111/cmi.12308
28. Ferrari S, Mulè S, Parini F, et al. The influence of the gut-brain axis on anxiety and depression: A review of the literature on the use of probiotics. J Tradit Complement Med. 2024;14(3):237-255. doi:10.1016/j.jtcme.2024.03.011
29. Nemati M, Ebrahimi B, Montazeri-Najafabady N. Probiotics ameliorate endocrine disorders via modulating inflammatory pathways: a systematic review. Genes Nutr. 2024;19(1):7. doi:10.1186/s12263-024-00743-8
30. Hsu YC, Huang YY, Tsai SY, et al. Efficacy of Probiotic Supplements on Brain-Derived Neurotrophic Factor, Inflammatory Biomarkers, Oxidative Stress and Cognitive Function in Patients with Alzheimer’s Dementia: A 12-Week Randomized, Double-Blind Active-Controlled Study. Nutrients. 2023;16(1):16. doi:10.3390/nu16010016
31. Liu L, Wang H, Zhang H, et al. Toward a Deeper Understanding of Gut Microbiome in Depression: The Promise of Clinical Applicability. Adv Sci. 2022;9(35):2203707. doi:10.1002/advs.202203707
32. Zhang Q, Chen B, Zhang J, et al. Effect of prebiotics, probiotics, synbiotics on depression: results from a meta-analysis. BMC Psychiatry. 2023;23(1):477. doi:10.1186/s12888-023-04963-x
33. Nikolova V, Cleare A, Young A, Stone J. Updated Review and Meta-Analysis of Probiotics for the Treatment of Clinical Depression: Adjunctive vs. Stand-Alone Treatment. J Clin Med. 2021;10(4):647. doi:10.3390/jcm10040647
34. Zhao S, Liang S, Tao J, et al. Probiotics for adults with major depressive disorder compared with antidepressants: a systematic review and network meta-analysis. Nutr Rev. Published online January 14, 2024:nuad171. doi:10.1093/nutrit/nuad171
35. Nikolova VL, Cleare AJ, Young AH, Stone JM. Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2023;80(8):842. doi:10.1001/jamapsychiatry.2023.1817
36. Schaub AC, Schneider E, Vazquez-Castellanos JF, et al. Clinical, gut microbial and neural effects of a probiotic add-on therapy in depressed patients: a randomized controlled trial. Transl Psychiatry. 2022;12(1):227. doi:10.1038/s41398-022-01977-z
37. Ullah H, Di Minno A, Esposito C, et al. Efficacy of a food supplement based on S-adenosyl methionine and probiotic strains in subjects with subthreshold depression and mild-to-moderate depression: A monocentric, randomized, cross-over, double-blind, placebo-controlled clinical trial. Biomed Pharmacother. 2022;156:113930. doi:10.1016/j.biopha.2022.113930
38. Sureda A, Tejada S. Polyphenols and depression: from chemistry to medicine. Curr Pharm Biotechnol. 2015;16(3):259-264. doi:10.2174/1389201016666150118133313
39. Gambini J, Inglés M, Olaso G, et al. Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans. Oxid Med Cell Longev. 2015;2015:e837042. doi:10.1155/2015/837042
40. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275(5297):218-220. doi:10.1126/science.275.5297.218
41. Bhullar KS, Hubbard BP. Lifespan and healthspan extension by resveratrol. Biochim Biophys Acta BBA - Mol Basis Dis. 2015;1852(6):1209-1218. doi:10.1016/j.bbadis.2015.01.012
42. Moore A, Beidler J, Hong MY. Resveratrol and Depression in Animal Models: A Systematic Review of the Biological Mechanisms. Molecules. 2018;23(9):2197. doi:10.3390/molecules23092197
43. Chen WQ, Zhao XL, Hou Y, et al. Protective effects of green tea polyphenols on cognitive impairments induced by psychological stress in rats. Behav Brain Res. 2009;202(1):71-76. doi:10.1016/j.bbr.2009.03.017
44. Hidese S, Ogawa S, Ota M, et al. Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial. Nutrients. 2019;11(10):2362. doi:10.3390/nu11102362
45. Kimura K, Ozeki M, Juneja LR, Ohira H. l-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007;74(1):39-45. doi:10.1016/j.biopsycho.2006.06.006
46. Pittenger C, Duman RS. Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms. Neuropsychopharmacology. 2008;33(1):88-109. doi:10.1038/sj.npp.1301574
47. Yaegashi A, Kimura T, Hirata T, Tamakoshi A. Green Tea Consumption and Risk of Depression Symptoms: A Systematic Review and Meta-Analysis of Observational Studies. J Nutr Sci Vitaminol (Tokyo). 2022;68(3):155-161. doi:10.3177/jnsv.68.155
48. Swardfager W, Herrmann N, Mazereeuw G, Goldberger K, Harimoto T, Lanctôt KL. Zinc in Depression: A Meta-Analysis. Biol Psychiatry. 2013;74(12):872-878. doi:10.1016/j.biopsych.2013.05.008
49. Wang J, Um P, Dickerman BA, Liu J. Zinc, Magnesium, Selenium and Depression: A Review of the Evidence, Potential Mechanisms and Implications. Nutrients. 2018;10(5):584. doi:10.3390/nu10050584
50. Testing the concentration of zinc in blood serum. Accessed April 27, 2024. http://www.mp.pl/social/article/174197
51. DiGirolamo AM, Ramirez-Zea M, Wang M, et al. Randomized trial of the effect of zinc supplementation on the mental health of school-age children in Guatemala. Am J Clin Nutr. 2010;92(5):1241-1250. doi:10.3945/ajcn.2010.29686
52. Gibson RS. Principles of Nutritional Assessment. Oxford University Press; 2005.
53. Maserejian NN, Hall SA, McKinlay JB. Low dietary or supplemental zinc is associated with depression symptoms among women, but not men, in a population-based epidemiological survey. J Affect Disord. 2012;136(3):781-788. doi:10.1016/j.jad.2011.09.039
54. Gröber U, Schmidt J, Kisters K. Magnesium in Prevention and Therapy. Nutrients. 2015;7(9):8199-8226. doi:10.3390/nu7095388
55. Stroebel D, Casado M, Paoletti P. Triheteromeric NMDA receptors: from structure to synaptic physiology. Curr Opin Physiol. 2018;2:1-12. doi:10.1016/j.cophys.2017.12.004
56. Kirkland AE, Sarlo GL, Holton KF. The Role of Magnesium in Neurological Disorders. Nutrients. 2018;10(6):730. doi:10.3390/nu10060730
57. Li B, Lv J, Wang W, Zhang D. Dietary magnesium and calcium intake and risk of depression in the general population: A meta-analysis. Aust N Z J Psychiatry. 2017;51(3):219-229. doi:10.1177/0004867416676895
58. Tarleton EK, Littenberg B. Magnesium Intake and Depression in Adults. J Am Board Fam Med. 2015;28(2):249-256. doi:10.3122/jabfm.2015.02.140176
59. Pasco JA, Jacka FN, Williams LJ, et al. Dietary selenium and major depression: a nested case-control study. Complement Ther Med. 2012;20(3):119-123. doi:10.1016/j.ctim.2011.12.008
60. Ekinci GN, Sanlier N. The relationship between nutrition and depression in the life process: A mini-review. Exp Gerontol. 2023;172:112072. doi:10.1016/j.exger.2022.112072
61. Brüning CA, Souza ACG, Gai BM, Zeni G, Nogueira CW. Antidepressant-like effect of m-trifluoromethyl-diphenyl diselenide in the mouse forced swimming test involves opioid and serotonergic systems. Eur J Pharmacol. 2011;658(2):145-149. doi:10.1016/j.ejphar.2011.02.039
62. Berridge MJ. Vitamin D and Depression: Cellular and Regulatory Mechanisms. Barker EL, ed. Pharmacol Rev. 2017;69(2):80-92. doi:10.1124/pr.116.013227
63. Maffei ME. 5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology. Int J Mol Sci. 2021;22(1):181. doi:10.3390/ijms22010181
64. Ceolin G, Mano GPR, Hames NS, et al. Vitamin D, Depressive Symptoms, and Covid-19 Pandemic. Front Neurosci. 2021;15. doi:10.3389/fnins.2021.670879
65. Alghamdi S, Alsulami N, Khoja S, Alsufiani H, Tayeb HO, Tarazi FI. Vitamin D Supplementation Ameliorates Severity of Major Depressive Disorder. J Mol Neurosci. 2020;70(2):230-235. doi:10.1007/s12031-019-01461-2
66. Mesripour A, Hajhashemi V, Kuchak A. Effect of concomitant administration of three different antidepressants with vitamin B6 on depression and obsessive compulsive disorder in mice models. Res Pharm Sci. 2017;12(1):46. doi:10.4103/1735-5362.199046
67. Kafeshani M, Feizi A, Esmaillzadeh A, et al. Higher vitamin B6 intake is associated with lower depression and anxiety risk in women but not in men: A large cross-sectional study. Int J Vitam Nutr Res. 2020;90(5-6):484-492. doi:10.1024/0300-9831/a000589
68. Mesripour A, Alhimma F, Hajhashemi V. The effect of vitamin B6 on dexamethasone-induced depression in mice model of despair. Nutr Neurosci. 2019;22(10):744-749. doi:10.1080/1028415X.2018.1442184
69. Bender A, Hagan KE, Kingston N. The association of folate and depression: A meta-analysis. J Psychiatr Res. 2017;95:9-18. doi:10.1016/j.jpsychires.2017.07.019
70. Pan LA, Martin P, Zimmer T, et al. Neurometabolic Disorders: Potentially Treatable Abnormalities in Patients With Treatment-Refractory Depression and Suicidal Behavior. Am J Psychiatry. 2017;174(1):42-50. doi:10.1176/appi.ajp.2016.15111500
71. Ferguson JM. SSRI Antidepressant Medications: Adverse Effects and Tolerability. Published online 2001.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Michał Sęk, Iwona Galasińska, Katarzyna Hajduk-Maślak, Beniamin Michalik, Adrianna Skóra, Dominik Zając
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 173
Number of citations: 0
